Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lenvatinib Induces Immunogenic Cell Death and Triggers Toll-Like Receptor-3/4 Ligands in Hepatocellular Carcinoma
Cheng Zhou, Zhangfu Yang, Bao‐Ye Sun, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 697-712
Open Access | Times Cited: 20

Showing 20 citing articles:

Hepatocellular carcinoma: signaling pathways and therapeutic advances
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 6
New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma—Today and Tomorrow
Rafał Becht, Kajetan Kiełbowski, Michał Wasilewicz
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1456-1456
Open Access | Times Cited: 10
Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer
Yunong Xie, Haofeng Wu, Yimiao He, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 2
Open Access | Times Cited: 10
Programmed cell death in hepatocellular carcinoma: mechanisms and therapeutic prospects
Xiang’an Wu, Jingying Cao, Xueshuai Wan, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Investigating autophagy and intricate cellular mechanisms in hepatocellular carcinoma: Emphasis on cell death mechanism crosstalk
Gang Wang, Xiaodi Jiang, Pedram Torabian, et al.
Cancer Letters (2024) Vol. 588, pp. 216744-216744
Open Access | Times Cited: 6
The Tumor Microenvironment Mediates the HIF-1α/PD-L1 Pathway to Promote Immune Escape in Colorectal Cancer
Jing Sun, Zhengtian Zhao, Jiaqi Lu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3735-3735
Open Access | Times Cited: 4
Lenvatinib enhances antitumor immunity of anti-PD-1 antibody
Yu Kato
International Journal of Clinical Oncology (2025)
Open Access
Dual-responsive magnetic vortex nanorings co-deliver lenvatinib and localized heat for synergistic activation of antitumor immunity
Zirui Ye, Bin Yan, Hugang Li, et al.
Acta Biomaterialia (2025)
Closed Access
Plant-derived natural compounds: A new frontier in inducing immunogenic cell death for cancer treatment
Lijuan Yang, Ting Han, Ruonan Liu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117099-117099
Closed Access | Times Cited: 3
Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing to Identify an Immunogenic Cell Death-Related 5-Gene Prognostic Signature in Hepatocellular Carcinoma
Liqun Peng, Shaohua Xu, Jianliang Xu
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 879-900
Open Access | Times Cited: 2
Boosting immune responses in lung tumor immune microenvironment: A comprehensive review of strategies and adjuvants
Fei Gao, Xiaoqing You, Liu Yang, et al.
International Reviews of Immunology (2024) Vol. 43, Iss. 5, pp. 280-308
Closed Access | Times Cited: 1
Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment
Eric A. Smith, R.L. Belote, Nelly M. Cruz, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Insights into Metabolic Reprogramming in Tumor Evolution and Therapy
Ching‐Feng Chiu, Jonathan Jaime G. Guerrero, Ric Ryan H. Regalado, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3513-3513
Open Access | Times Cited: 1
Beclin-1: a therapeutic target at the intersection of autophagy, immunotherapy, and cancer treatment
Zhijun Cao, Ke Tian, Yincheng Ran, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
The Functional Mechanisms of Toll-Like Receptor 3 and Its Implications in Digestive System Tumors
Bin Han, Chao Zhang, Xiaoxiao Wang, et al.
Frontiers in Bioscience-Landmark (2023) Vol. 28, Iss. 11, pp. 297-297
Open Access | Times Cited: 3
Novel Insights into the Regulation of Exosomal PD-L1 in Cancer: From Generation to Clinical Application
Jie Liu, Junxia Qin, Lili Liang, et al.
European Journal of Pharmacology (2024) Vol. 979, pp. 176831-176831
Closed Access
Progress in Research on Immunogenic Cell Death and Its Application in Hepatocellular Carcinoma Therapy
辰宇 巩
Advances in Clinical Medicine (2024) Vol. 14, Iss. 09, pp. 1025-1033
Closed Access
Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review)
Ganghui Ye, Meng Ye, Xin Jin
American Journal of Cancer Research (2024) Vol. 14, Iss. 9, pp. 4113-4171
Closed Access
Discovery of Daclatasvir as a potential PD-L1 inhibitor from drug repurposing
Mengmeng Sun, Shixuan Lv, Yanyan Pan, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107874-107874
Closed Access
Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment
Eric A. Smith, R.L. Belote, Nelly M. Cruz, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access
Page 1

Scroll to top